17918180	207	Fraser M	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.	International journal of cancer	2008	50
23897969	207	Iyer G	Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer.	Journal of clinical oncology 	2013	58
25185240	207	Rothé F	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.	Annals of oncology 	2014	35
23091097	472	Skowronska A	Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.	Journal of clinical oncology 	2012	32
23620409	472	Biddlestone-Thorpe L	ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.	Clinical cancer research 	2013	32
27069256	596	Anderson MA	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.	Blood	2016	15
15910949	672	Leach MO	Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS).	Lancet	2005	156
16522644	672	Mathe E	Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.	Nucleic acids research	2006	81
20606085	672	Hennessy BT	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.	Journal of clinical oncology 	2010	67
21505135	672	Link DC	Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.	JAMA	2011	59
24218601	672	Etemadmoghadam D	Synthetic lethality between CCNE1 amplification and loss of BRCA1.	Proceedings of the National Academy of Sciences of the United States of America	2013	31
23856246	673	Abaan OD	The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.	Cancer research	2013	80
21412932	1019	Birnbaum DJ	Genome profiling of pancreatic adenocarcinoma.	Genes, chromosomes and cancer	2011	43
25719666	1021	Waddell N	Whole genomes redefine the mutational landscape of pancreatic cancer.	Nature	2015	212
20507599	1026	Baba Y	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors.	Molecular cancer	2010	50
27323328	1026	Galanos P	Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing.	Nature cell biology	2016	18
26551667	1027	da Silva Almeida AC	The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.	Nature genetics	2015	27
9776413	1029	Cairncross JG	Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.	Journal of the National Cancer Institute	1998	181
10319873	1029	Barrett MT	Evolution of neoplastic cell lineages in Barrett oesophagus.	Nature genetics	1999	97
10416987	1029	Ishii N	Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.	Brain pathology	1999	155
15466178	1029	Ohgaki H	Genetic pathways to glioblastoma: a population-based study.	Cancer research	2004	282
15899794	1029	Rich JN	Gene expression profiling and genetic markers in glioblastoma survival.	Cancer research	2005	78
15977639	1029	Ohgaki H	Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.	Journal of neuropathology and experimental neurology	2005	237
16799619	1029	Laurent-Puig P	Genetics of hepatocellular tumors.	Oncogene	2006	82
17088437	1029	Ikediobi ON	Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.	Molecular cancer therapeutics	2006	152
17326708	1029	Galipeau PC	NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.	PLoS medicine	2007	87
17456751	1029	Ohgaki H	Genetic pathways to primary and secondary glioblastoma.	The American journal of pathology	2007	299
20068183	1029	Schiffman JD	Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.	Cancer research	2010	86
20451455	1029	Marur S	HPV-associated head and neck cancer: a virus-related cancer epidemic.	The Lancet. Oncology	2010	283
22067401	1029	Oberholzer PA	RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.	Journal of clinical oncology 	2012	79
22256804	1029	Su F	RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.	The New England journal of medicine	2012	200
23470568	1029	Oshima M	Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.	Annals of surgery	2013	42
23601657	1029	Riaz M	miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.	Breast cancer research 	2013	38
23887298	1029	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	36
23907151	1029	Kanagal-Shamanna R	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.	Modern pathology 	2014	32
24127483	1029	Fabbri G	Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome.	The Journal of experimental medicine	2013	26
25009010	1029	De Mattos-Arruda L	Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.	Annals of oncology 	2014	47
25010205	1029	Brohl AS	The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.	PLoS genetics	2014	53
25092538	1029	Kim PH	Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.	European urology	2015	19
25117714	1029	Ozawa T	Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.	Cancer cell	2014	54
25223734	1029	Tirode F	Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.	Cancer discovery	2014	57
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
25503501	1029	Maxwell KN	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.	Genetics in medicine 	2015	24
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
25589618	1029	Li YY	Genomic analysis of metastatic cutaneous squamous cell carcinoma.	Clinical cancer research 	2015	17
25712460	1029	Chung CH	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.	Annals of oncology 	2015	17
25822088	1029	Schulze K	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.	Nature genetics	2015	104
26099527	1029	Zucman-Rossi J	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.	Gastroenterology	2015	47
26192918	1029	Stachler MD	Paired exome analysis of Barrett's esophagus and adenocarcinoma.	Nature genetics	2015	30
26551670	1029	Wang L	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.	Nature genetics	2015	24
26830752	1029	Kamisawa T	Pancreatic cancer.	Lancet	2016	47
26873401	1029	Sawada G	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.	Gastroenterology	2016	17
27213815	1029	Dauch D	A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.	Nature medicine	2016	15
22104201	1045	Jang BG	Molecular pathology of gastric carcinoma.	Pathobiology 	2011	41
24487413	1050	Kihara R	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.	Leukemia	2014	34
23242585	1111	Ma CX	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.	Breast cancer research and treatment	2013	27
22941188	1387	Peifer M	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.	Nature genetics	2012	215
15761464	1499	Bell DA	Origins and molecular pathology of ovarian cancer.	Modern pathology 	2005	100
17187432	1499	Boyault S	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.	Hepatology	2007	191
22653804	1499	McConechy MK	Use of mutation profiles to refine the classification of endometrial carcinomas.	The Journal of pathology	2012	45
22820256	1499	Pugh TJ	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.	Nature	2012	203
22975805	1499	Seo JS	The transcriptional landscape and mutational profile of lung adenocarcinoma.	Genome research	2012	139
23325582	1499	Peeters M	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.	Clinical cancer research 	2013	56
23337059	1499	Wangefjord S	Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.	Diagnostic pathology	2013	27
23636398	1499	Cancer Genome Atlas Research Network.	Integrated genomic characterization of endometrial carcinoma.	Nature	2013	552
23765252	1499	McConechy MK	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.	Modern pathology 	2014	25
23780408	1499	Bashashati A	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.	The Journal of pathology	2013	80
23788652	1499	Kan Z	Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.	Genome research	2013	95
23979959	1499	Nikiforova MN	Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.	The Journal of clinical endocrinology and metabolism	2013	52
25248380	1499	Friemel J	Intratumor heterogeneity in hepatocellular carcinoma.	Clinical cancer research 	2015	28
25490274	1499	Juhlin CC	Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma.	The Journal of clinical endocrinology and metabolism	2015	17
26192917	1654	Jiang L	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.	Nature genetics	2015	30
23704090	1788	Krönke J	Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.	Blood	2013	42
15604253	1956	Kosaka T	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.	Cancer research	2004	233
16757721	1956	Carey LA	Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.	JAMA	2006	957
17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
19723643	1956	Krishnaswamy S	Ethnic differences and functional analysis of MET mutations in lung cancer.	Clinical cancer research 	2009	55
20855837	1956	Sun Y	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.	Journal of clinical oncology 	2010	93
20864632	1956	Attolini CS	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
22590557	1956	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	45
22649089	1956	Forshew T	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.	Science translational medicine	2012	209
23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
25593300	1956	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	18
26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	14
26477306	1956	Schabath MB	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.	Oncogene	2016	11
26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
18772890	2064	Cancer Genome Atlas Research Network.	Comprehensive genomic characterization defines human glioblastoma genes and core pathways.	Nature	2008	2168
21373875	2064	Glück S	TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.	Breast cancer research and treatment	2012	58
22495314	2064	Shah SP	The clonal and mutational evolution spectrum of primary triple-negative breast cancers.	Nature	2012	499
25713166	2064	Ng CK	Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights.	Journal of the National Cancer Institute	2015	20
16897746	2099	Bergamaschi A	Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.	Genes, chromosomes and cancer	2006	161
25979954	2099	Guttery DS	Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.	Clinical chemistry	2015	22
26563128	2099	Ma CX	A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.	Clinical cancer research 	2016	13
22869879	2146	Bejar R	Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.	Journal of clinical oncology 	2012	90
26501191	2146	Huang L	Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.	Nature medicine	2015	19
23619168	2195	Pickering CR	Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.	Cancer discovery	2013	110
24292195	2195	India Project Team of the International Cancer Genome Consortium.	Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.	Nature communications	2013	61
22493262	2261	Chen CH	Aristolochic acid-associated urothelial cancer in Taiwan.	Proceedings of the National Academy of Sciences of the United States of America	2012	55
26901314	2261	Ward DG	Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.	PloS one	2016	11
21518729	2305	Millour J	ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.	Molecular cancer therapeutics	2011	38
21720365	2305	Cancer Genome Atlas Research Network.	Integrated genomic analyses of ovarian carcinoma.	Nature	2011	1665
25512523	2475	Perry JA	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.	Proceedings of the National Academy of Sciences of the United States of America	2014	46
25238946	2956	Lancaster JM	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.	Gynecologic oncology	2015	24
26061751	3075	Cancer Genome Atlas Research Network.	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.	The New England journal of medicine	2015	209
15572290	3251	DeMarini DM	Genotoxicity of tobacco smoke and tobacco smoke condensate: a review.	Mutation research	2004	95
25514803	3265	Lo Iacono M	Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.	Journal of thoracic oncology 	2015	21
19246647	3417	Watanabe T	IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.	The American journal of pathology	2009	185
19805672	3417	Weller M	Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.	Journal of clinical oncology 	2009	135
21075857	3417	Kim YH	Molecular classification of low-grade diffuse gliomas.	The American journal of pathology	2010	43
21163902	3417	Christensen BC	DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.	Journal of the National Cancer Institute	2011	89
22180306	3417	Borger DR	Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.	The oncologist	2012	126
22415316	3417	Gorovets D	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.	Clinical cancer research 	2012	40
25091696	3417	Tang X	A joint analysis of metabolomics and genetics of breast cancer.	Breast cancer research 	2014	26
25143301	3417	Sahm F	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.	Acta neuropathologica	2014	32
27276561	3418	Papaemmanuil E	Genomic Classification and Prognosis in Acute Myeloid Leukemia.	The New England journal of medicine	2016	79
20008300	3717	Beer PA	Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.	Blood	2010	63
24478400	3717	Lundberg P	Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.	Blood	2014	71
22665543	3845	Vakiani E	Comparative genomic analysis of primary versus metastatic colorectal carcinomas.	Journal of clinical oncology 	2012	67
23912084	3845	Murphy SJ	Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor.	Gastroenterology	2013	33
24042191	3845	Mouradov D	Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations.	The American journal of gastroenterology	2013	27
24385213	3845	Tahara T	Fusobacterium in colonic flora and molecular features of colorectal carcinoma.	Cancer research	2014	46
24398677	3845	Kahlert C	Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer.	The Journal of biological chemistry	2014	94
25051912	3845	Zoratto F	Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis.	Tumour biology 	2014	35
25706875	3845	Matano M	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.	Nature medicine	2015	74
26085511	3845	Frenel JS	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.	Clinical cancer research 	2015	31
26216840	3845	Carethers JM	Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer.	Gastroenterology	2015	32
19584151	4089	Blackford A	SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.	Clinical cancer research 	2009	91
27432539	4089	Yu J	Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms.	Gut	2017	5
19935675	4193	Brown CJ	Awakening guardian angels: drugging the p53 pathway.	Nature reviews. Cancer	2009	252
20975744	4193	Cheok CF	Translating p53 into the clinic.	Nature reviews. Clinical oncology	2011	118
23084521	4193	Ray-Coquard I	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.	The Lancet. Oncology	2012	111
24356649	4193	Zheng T	Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis.	Nature communications	2013	34
25477334	4193	Meng X	MDM2-p53 pathway in hepatocellular carcinoma.	Cancer research	2014	23
25621662	4193	Macheret M	DNA replication stress as a hallmark of cancer.	Annual review of pathology	2015	55
22156295	4292	Wang L	Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency.	Genome research	2012	33
26331536	4297	Zhu J	Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth.	Nature	2015	51
26099045	4609	Yates LR	Subclonal diversification of primary breast cancer revealed by multiregion sequencing.	Nature medicine	2015	74
26005866	4610	Boutros PC	Spatial genomic heterogeneity within localized, multifocal prostate cancer.	Nature genetics	2015	56
25533335	4613	Hill RM	Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.	Cancer cell	2015	18
27040285	4613	Ramaswamy V	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.	Acta neuropathologica	2016	17
22544022	4763	Carter SL	Absolute quantification of somatic DNA alterations in human cancer.	Nature biotechnology	2012	316
26580448	4763	Zhang J	Germline Mutations in Predisposition Genes in Pediatric Cancer.	The New England journal of medicine	2015	43
20007775	4851	Westhoff B	Alterations of the Notch pathway in lung cancer.	Proceedings of the National Academy of Sciences of the United States of America	2009	110
21798897	4851	Agrawal N	Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.	Science	2011	496
22006338	4851	Wang NJ	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.	Proceedings of the National Academy of Sciences of the United States of America	2011	108
22077063	4851	Rossi D	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.	Blood	2012	63
22207691	4851	Del Giudice I	NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.	Haematologica	2012	36
22210878	4851	Kridel R	Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.	Blood	2012	52
23392294	4893	Kinsler VA	Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.	The Journal of investigative dermatology	2013	31
25148578	4893	Siroy AE	Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.	The Journal of investigative dermatology	2015	17
19349352	5290	Kuo KT	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.	The American journal of pathology	2009	89
22923510	5290	Kuhn E	Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.	Journal of the National Cancer Institute	2012	58
23532889	5290	Shigaki H	PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.	Clinical cancer research 	2013	28
23739063	5290	Loi S	Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.	Journal of the National Cancer Institute	2013	34
25228659	5295	Shinbrot E	Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication.	Genome research	2014	34
22628410	5728	Martins FC	Evolutionary pathways in BRCA1-associated breast tumors.	Cancer discovery	2012	41
25190698	5728	Daly MB	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.	Journal of the National Comprehensive Cancer Network 	2014	30
26546618	5728	Aparicio AM	Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.	Clinical cancer research 	2016	11
15240783	5925	Braakhuis BJ	Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus.	Journal of the National Cancer Institute	2004	87
18211953	5925	Dimaras H	Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma.	Human molecular genetics	2008	58
18782450	5925	Herschkowitz JI	The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas.	Breast cancer research 	2008	86
26168399	5925	George J	Comprehensive genomic profiles of small cell lung cancer.	Nature	2015	94
23955565	7015	Nonoguchi N	TERT promoter mutations in primary and secondary glioblastomas.	Acta neuropathologica	2013	40
25314060	7015	Labussière M	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.	British journal of cancer	2014	28
8423624	7157	Allred DC	Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.	Journal of the National Cancer Institute	1993	132
11902578	7157	Soussi T	Assessing TP53 status in human tumours to evaluate clinical outcome.	Nature reviews. Cancer	2001	128
12007217	7157	Olivier M	The IARC TP53 database: new online mutation analysis and recommendations to users.	Human mutation	2002	267
12826609	7157	Kato S	Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.	Proceedings of the National Academy of Sciences of the United States of America	2003	156
15685439	7157	Ohgaki H	Epidemiology and etiology of gliomas.	Acta neuropathologica	2005	212
16170357	7157	Bossi G	Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression.	Oncogene	2006	68
16172461	7157	Russo A	The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.	Journal of clinical oncology 	2005	72
16489069	7157	Olivier M	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.	Clinical cancer research 	2006	119
17311302	7157	Petitjean A	Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.	Human mutation	2007	457
17401424	7157	Petitjean A	TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes.	Oncogene	2007	190
17417627	7157	Song H	p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.	Nature cell biology	2007	112
17504517	7157	Langerød A	TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.	Breast cancer research 	2007	93
17517648	7157	Dahl F	Multigene amplification and massively parallel sequencing for cancer mutation discovery.	Proceedings of the National Academy of Sciences of the United States of America	2007	57
17936556	7157	Soussi T	Shaping genetic alterations in human cancer: the p53 mutation paradigm.	Cancer cell	2007	102
18094375	7157	Patocs A	Breast-cancer stromal cells with TP53 mutations and nodal metastases.	The New England journal of medicine	2007	93
18094376	7157	Poeta ML	TP53 mutations and survival in squamous-cell carcinoma of the head and neck.	The New England journal of medicine	2007	160
18685109	7157	Shlien A	Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.	Proceedings of the National Academy of Sciences of the United States of America	2008	51
18689542	7157	Zenz T	Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.	Blood	2008	76
19165225	7157	Whibley C	p53 polymorphisms: cancer implications.	Nature reviews. Cancer	2009	125
19188171	7157	Rossi D	The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.	Clinical cancer research 	2009	48
19308457	7157	Pfeifer GP	Mutational spectra of human cancer.	Human genetics	2009	69
20123995	7157	Thompson SL	Proliferation of aneuploid human cells is limited by a p53-dependent mechanism.	The Journal of cell biology	2010	142
20182602	7157	Olivier M	TP53 mutations in human cancers: origins, consequences, and clinical use.	Cold Spring Harbor perspectives in biology	2010	236
20182618	7157	Oren M	Mutant p53 gain-of-function in cancer.	Cold Spring Harbor perspectives in biology	2010	181
20229506	7157	Ahmed AA	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.	The Journal of pathology	2010	149
20697090	7157	Zenz T	TP53 mutation and survival in chronic lymphocytic leukemia.	Journal of clinical oncology 	2010	91
20871609	7157	Swarbrick A	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma.	Nature medicine	2010	52
20952405	7157	Forbes SA	COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.	Nucleic acids research	2011	834
21205967	7157	Fabbri M	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.	JAMA	2011	72
21331359	7157	Mogi A	TP53 mutations in nonsmall cell lung cancer.	Journal of biomedicine and biotechnology	2011	45
21364938	7157	Enerly E	miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.	PloS one	2011	115
21483000	7157	Gonzalez D	Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.	Journal of clinical oncology 	2011	47
21519010	7157	Jädersten M	TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.	Journal of clinical oncology 	2011	69
21601526	7157	Villani A	Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.	The Lancet. Oncology	2011	46
21747090	7157	Hof J	Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.	Journal of clinical oncology 	2011	41
21765642	7157	Suzuki K	Recent advances in p53 research and cancer treatment.	Journal of biomedicine and biotechnology	2011	40
21941372	7157	Marcel V	Biological functions of p53 isoforms through evolution: lessons from animal and cellular models.	Cell death and differentiation	2011	65
22090360	7157	Skinner HD	TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.	Clinical cancer research 	2012	58
22186996	7157	Rücker FG	TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.	Blood	2012	69
22265402	7157	Rausch T	Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations.	Cell	2012	175
22265415	7157	Freed-Pastor WA	Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.	Cell	2012	163
22297721	7157	Pospisilova S	ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.	Leukemia	2012	38
22549840	7157	Gerstung M	Reliable detection of subclonal single-nucleotide variants in tumour cell populations.	Nature communications	2012	55
22715097	7157	Ano Bom AP	Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.	The Journal of biological chemistry	2012	41
22822097	7157	Walerych D	The rebel angel: mutant p53 as the driving oncogene in breast cancer.	Carcinogenesis	2012	61
22955915	7157	Xu-Monette ZY	Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.	Blood	2012	42
23297687	7157	Kulasekararaj AG	TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.	British journal of haematology	2013	44
23630207	7157	Vignot S	Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.	Journal of clinical oncology 	2013	38
23644491	7157	Kadoch C	Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.	Nature genetics	2013	169
23649806	7157	Kleiblova P	Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.	The Journal of cell biology	2013	33
23835706	7157	Zhukova N	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.	Journal of clinical oncology 	2013	43
23913924	7157	Vakifahmetoglu-Norberg H	Chaperone-mediated autophagy degrades mutant p53.	Genes and development	2013	30
24138928	7157	Horvath S	DNA methylation age of human tissues and cell types.	Genome biology	2013	377
24379683	7157	Surget S	Uncovering the role of p53 splice variants in human malignancy: a clinical perspective.	OncoTargets and therapy	2013	39
24469795	7157	Morrison CD	Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	24
24487586	7157	Arjonen A	Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis.	The Journal of clinical investigation	2014	36
24501221	7157	Rossi D	Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia.	Blood	2014	50
24630730	7157	Supek F	Synonymous mutations frequently act as driver mutations in human cancers.	Cell	2014	76
24642672	7157	McBride KA	Li-Fraumeni syndrome: cancer risk assessment and clinical management.	Nature reviews. Clinical oncology	2014	25
24658082	7157	Powell E	Contribution of p53 to metastasis.	Cancer discovery	2014	38
24665023	7157	Leroy B	TP53 mutations in human cancer: database reassessment and prospects for the next decade.	Human mutation	2014	28
24682512	7157	Saft L	p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).	Haematologica	2014	22
24768524	7157	Bykov VJ	Mutant p53 reactivation by small molecules makes its way to the clinic.	FEBS letters	2014	32
25086664	7157	Gross AM	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss.	Nature genetics	2014	32
25287991	7157	Malcikova J	Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.	Leukemia	2015	18
25482194	7157	James A	Nucleolar stress with and without p53.	Nucleus	2014	41
25538195	7157	Vieira VC	Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.	mBio	2014	33
25555420	7157	Farooqui MZ	Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.	The Lancet. Oncology	2015	51
25634208	7157	Neskey DM	Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.	Cancer research	2015	19
25827447	7157	Hong MK	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer.	Nature communications	2015	39
25894828	7157	Cristescu R	Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.	Nature medicine	2015	84
26014290	7157	Bougeard G	Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.	Journal of clinical oncology 	2015	20
26024390	7157	Soussi T	TP53: an oncogene in disguise.	Cell death and differentiation	2015	26
26605532	7157	Jin W	Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples.	Nature	2015	31
27009395	7157	Stracquadanio G	The importance of p53 pathway genetics in inherited and somatic cancer genomes.	Nature reviews. Cancer	2016	19
27328919	7157	Bouaoun L	TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data.	Human mutation	2016	12
27377626	7157	Fernandez-Cuesta L	Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer.	EBioMedicine	2016	13
22722202	10000	Banerji S	Sequence analysis of mutations and translocations across breast cancer subtypes.	Nature	2012	320
24608573	10000	Meric-Bernstam F	Concordance of genomic alterations between primary and recurrent breast cancer.	Molecular cancer therapeutics	2014	21
25122428	10000	Umemura S	Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.	Journal of thoracic oncology 	2014	21
19092773	10111	Ripperger T	Breast cancer susceptibility: current knowledge and implications for genetic counselling.	European journal of human genetics 	2009	45
22006311	10111	Walsh T	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2011	149
24136165	10735	Cazzola M	The genetic basis of myelodysplasia and its clinical relevance.	Blood	2013	59
10617473	11200	Bell DW	Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.	Science	1999	140
16551709	11200	Walsh T	Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.	JAMA	2006	143
21960636	11200	Janssen A	Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations.	Science	2011	143
24549055	11200	Castéra L	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.	European journal of human genetics 	2014	39
24434212	22894	Lohr JG	Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.	Cancer cell	2014	147
17964266	23411	Kim EJ	Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity.	Molecular cell	2007	138
18203716	23411	Li K	Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation.	The Journal of biological chemistry	2008	53
23086750	23451	Oscier DG	The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.	Blood	2013	51
23415222	23451	Landau DA	Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.	Cell	2013	299
24113472	23451	Jeromin S	SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.	Leukemia	2014	37
24652989	23451	Stilgenbauer S	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.	Blood	2014	49
24943832	23451	Baliakas P	Recurrent mutations refine prognosis in chronic lymphocytic leukemia.	Leukemia	2015	46
25957392	23451	Malcovati L	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.	Blood	2015	25
26675346	23451	Ljungström V	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.	Blood	2016	12
26837699	23451	Nadeu F	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.	Blood	2016	15
23720127	54474	Hallek M	Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment.	American journal of hematology	2013	37
25908509	54474	Hallek M	Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.	American journal of hematology	2015	38
22810696	139285	Cancer Genome Atlas Network.	Comprehensive molecular characterization of human colon and rectal cancer.	Nature	2012	1543
25455730	145270	Duffy MJ	p53 as a target for the treatment of cancer.	Cancer treatment reviews	2014	38
21714648	171023	Bejar R	Clinical effect of point mutations in myelodysplastic syndromes.	The New England journal of medicine	2011	261
22343920	171023	Damm F	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.	Blood	2012	47
22915647	171023	Grossmann V	A novel hierarchical prognostic model of AML solely based on molecular mutations.	Blood	2012	37
23690417	171023	Itzykson R	Prognostic score including gene mutations in chronic myelomonocytic leukemia.	Journal of clinical oncology 	2013	70
23958953	171023	Schwaab J	Comprehensive mutational profiling in advanced systemic mastocytosis.	Blood	2013	28
25092778	171023	Bejar R	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.	Journal of clinical oncology 	2014	40
25224413	171023	Bejar R	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.	Blood	2014	56
25326804	171023	Xie M	Age-related mutations associated with clonal hematopoietic expansion and malignancies.	Nature medicine	2014	168
23355908	196528	Shain AH	The spectrum of SWI/SNF mutations, ubiquitous in human cancers.	PloS one	2013	88
